Esperion Net Tangible Assets from 2010 to 2025
| ESPR Stock | USD 1.69 0.04 2.31% |
Net Tangible Assets | First Reported 2013-06-30 | Previous Quarter -372 M | Current Value -410.1 M | Quarterly Volatility 226.2 M |
Check Esperion Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Esperion Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 198 K, Interest Expense of 71.2 M or Gross Profit of 62.5 M, as well as many indicators such as Price To Sales Ratio of 2.9, Dividend Yield of 0.0 or Days Sales Outstanding of 88.37. Esperion financial statements analysis is a perfect complement when working with Esperion Therapeutics Valuation or Volatility modules.
Esperion | Net Tangible Assets |
Latest Esperion Therapeutics' Net Tangible Assets Growth Pattern
Below is the plot of the Net Tangible Assets of Esperion Therapeutics over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Esperion Therapeutics' Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Esperion Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Tangible Assets | 10 Years Trend |
|
Net Tangible Assets |
| Timeline |
Esperion Net Tangible Assets Regression Statistics
| Arithmetic Mean | (13,746,242) | |
| Geometric Mean | 137,449,282 | |
| Coefficient Of Variation | (1,523) | |
| Mean Deviation | 178,305,367 | |
| Median | 74,035,629 | |
| Standard Deviation | 209,314,441 | |
| Sample Variance | 43812.5T | |
| Range | 611M | |
| R-Value | (0.77) | |
| Mean Square Error | 19178.9T | |
| R-Squared | 0.59 | |
| Significance | 0.0005 | |
| Slope | (33,811,049) | |
| Total Sum of Squares | 657188T |
Esperion Net Tangible Assets History
About Esperion Therapeutics Financial Statements
Esperion Therapeutics shareholders use historical fundamental indicators, such as Net Tangible Assets, to determine how well the company is positioned to perform in the future. Although Esperion Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Esperion Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Esperion Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Tangible Assets | -291.4 M | -276.8 M |
Pair Trading with Esperion Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Esperion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Esperion Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Esperion Stock
| 0.6 | OPT | Opthea Earnings Call Today | PairCorr |
| 0.56 | GANX | Gain Therapeutics | PairCorr |
| 0.56 | PHGE | Biomx Inc | PairCorr |
| 0.49 | CUE | Cue Biopharma | PairCorr |
| 0.49 | PFE | Pfizer Inc Aggressive Push | PairCorr |
The ability to find closely correlated positions to Esperion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Esperion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Esperion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Esperion Therapeutics to buy it.
The correlation of Esperion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Esperion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Esperion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Esperion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Esperion Stock Analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.